For data that are unavailable in databases, trial tests were performed according to the Organization for Economic Co-operation and Development (OECD). The results of this study indicated that the established strategies and parameters enable the integration of different data to characterize the acute aquatic toxicity of cosmetic products and indicated that sunscreens comprised the class of products with the highest impact followed by triclosan bactericide and mineral oil emollient. Therefore, this study proved that the developed strategy provides a tool for efficiently mitigating the environmental impact of raw materials in rinse-off cosmetic products by replacing ingredients with higher environmental risk and increasing the use of sustainable cosmetic products that adhere to major international guidelines. Research and Development Unit, National Heart Centre Singapore, Singapore, Republic of Singapore Mitragyna speciosa Korth (Kratom) is known for its euphoric properties and is frequently used for recreational purposes in some western countries. Multiple poisoning and fatal cases involving Kratom and mitragynine have been reported but the underlying causes remain unclear. In most cases, combination use of drugs with this legal high was reported and post-mortem lung edema and congestion were found in some victims. Our research team aims to provide systematic in vitro cardiotoxicity and drug interaction risks data for mitragynine. We have investigated the effects of this compound on the cardiac potassium channels, cytochromes P450 enzymes and P-glcyoprotein transport activity. In our studies, mitragynine is found to inhibit IKr and IKACh currents mediated by hERG and GIRK potassium channels which are critical for the cardiac function. The hERG tail currents following depolarization pulses were inhibited by mitragynine with an IC50 value of 1.62 M, 1.15 M and 0.91 M in the hERG-transfected HEK293 cells, Xenopus oocytes and hiPSC cardiomyocytes respectively. Mitragynine also prolonged action potential duration in the cardiomyocytes. The S6 point mutations of Y652A and F656A attenuated the inhibitor effects of mitragynine, indicating that mitragynine interacts with these high affinity drug-binding sites in the hERG channel pore cavity which was consistent with the molecular docking simulation. Mitragynine is also found to be a significant in vitro CYP1A2 inducer and inhibits the P-glycoprotein transport activity of digoxin in Caco2 cells. Collectively, mitragynine poses a risk for cardiotoxicity and possible interactions with drugs. Helleborus niger L. (black hellebore, Christmas rose), a perennial herb of the Ranunculaceae family, is native to European Alpine regions. Besides being popular as ornamental plant, hellebore experiences an ever-growing scientific interest due to divergent pharmacological actions. Amongst others, anti-inflammatory, antifungal, or cytotoxic activities against tumour cells were reported. Amid its secondary metabolites, steroidal saponins,ˇ-ecdysone and the ranunculin derivative protoanemonin represent relevant pharmacologically active components.
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In vitro safety assessments of mitragynine, an euphoric compound isolated from Kratom, a herb-based legal high Research and Development Unit, National Heart Centre Singapore, Singapore, Republic of Singapore Mitragyna speciosa Korth (Kratom) is known for its euphoric properties and is frequently used for recreational purposes in some western countries. Multiple poisoning and fatal cases involving Kratom and mitragynine have been reported but the underlying causes remain unclear. In most cases, combination use of drugs with this legal high was reported and post-mortem lung edema and congestion were found in some victims. Our research team aims to provide systematic in vitro cardiotoxicity and drug interaction risks data for mitragynine. We have investigated the effects of this compound on the cardiac potassium channels, cytochromes P450 enzymes and P-glcyoprotein transport activity. In our studies, mitragynine is found to inhibit IKr and IKACh currents mediated by hERG and GIRK potassium channels which are critical for the cardiac function. The hERG tail currents following depolarization pulses were inhibited by mitragynine with an IC50 value of 1.62 M, 1.15 M and 0.91 M in the hERG-transfected HEK293 cells, Xenopus oocytes and hiPSC cardiomyocytes respectively. Mitragynine also prolonged action potential duration in the cardiomyocytes. The S6 point mutations of Y652A and F656A attenuated the inhibitor effects of mitragynine, indicating that mitragynine interacts with these high affinity drug-binding sites in the hERG channel pore cavity which was consistent with the molecular docking simulation. Mitragynine is also found to be a significant in vitro CYP1A2 inducer and inhibits the P-glycoprotein transport activity of digoxin in Caco2 cells. Collectively, mitragynine poses a risk for cardiotoxicity and possible interactions with drugs. Helleborus niger L. (black hellebore, Christmas rose), a perennial herb of the Ranunculaceae family, is native to European Alpine regions. Besides being popular as ornamental plant, hellebore experiences an ever-growing scientific interest due to divergent pharmacological actions. Amongst others, anti-inflammatory, antifungal, or cytotoxic activities against tumour cells were reported. Amid its secondary metabolites, steroidal saponins,ˇ-ecdysone and the ranunculin derivative protoanemonin represent relevant pharmacologically active components.
Though rare, many symptoms from poisoning with hellebore are attributed to the membranolytic properties of saponins. This is inter alia expressed by a haemolytic activity, hence a potential to disintegrate the cellular membrane of erythrocytes. Furthermore, protoanemonin has been suspected to exert a mutagenic potential. Still, toxicological investigations on Helleborus plant extracts have only rarely been published.
In the present study, an aqueous fermented extract of the whole plant H. niger L. produced according to pharmaceutical standards was analysed with regard to protoanemonin content and its steroidal saponin profile. Furthermore, in line with respective guidelines (EMEA/HMPC/107079/2007, 21st May 2008), the mutagenic potential was evaluated in a bacterial reverse mutation assay conducted with and without exogenous metabolic activation following OECD standards. Concomitantly, the haemolytic potential of the hellebore extract was investigated in human erythrocytes.
As a result, no evidence for genotoxicity was revealed. While the undiluted sample showed a certain haemolytic effect, no haemolysis was induced up to 10 L/mL, correlating with saponin levels. The data presented contribute to a better knowledge of the preclinical safety of aqueous fermented H. niger extracts and preparations thereof. The binary mixture of ethanol and of the clinically used antifungal fluconazole (FLUCO) has been tested on postimplantation rat whole embryos cultured in vitro (WEC method).
The mixture model "fix and moving" has been applied: E9.5 embryos were exposed in vitro to Eth (17-42.5-85-127 mM), FLUCO (62.5-125-250-500 M) or were co-exposed to the Eth NOAEL (17 mM) + the scaled concentrations of FLUCO or, vice versa, to the FLUCO NOAEL (62.5 M) + the scaled concentrations of Eth. At the end of the culture (48 h) embryos were morphologically examined to evaluate growth parameters and abnormalities.
Concentration-related effects were observed after the exposure to Eth (42.5-127 mM) or FLUCO (125-500 M). The observed abnormalities were, for FLUCO, specifically at the level of the branchial apparatus, while Eth was able to induce multiple abnormalities, including defects at the level of branchial arches. Based on bench mark dose (BMD) and relative potency factor (RPF) approaches, the outcome of mixtures were modelled and the predicted effects, derived under the dose-additivity hypothesis, compared with the experimentally obtained results. The coexposure to Eth and FLUCO produced a significant enhancement of teratogenic effects on branchial arches in comparison to the single exposures. In addition, the mixture of the two molecules at their NOAELs resulted effective too, inducing almost 40% branchial arch abnormalities. Results from BMD approach show that, regarding branchial arches abnormalities, there are no significant deviations from concentration-additivity and suggest that FLUCO and Eth share, limited to the branchial pathogenesis, the same mode of action. Submitted on behalf of the NC3Rs working group on monoclonal antibody (mAb) biosimilars. mAb biosimilars are biological products which are almost identical to mAbs in clinical use but produced by another manufacturer once the patent on the original ('innovator') product has expired. There are currently major differences between how biosimilars are regulated globally, leading to substantial variability in the amount of in vivo nonclinical toxicity testing required to support clinical development and marketing. There are approximately 30 national and international guidelines on biosimilar development. The European Union's guidance describes an approach that enables biosimilars to enter clinical trials based on robust in vitro data alone; in contrast, the World Health Organization's guidance is interpreted to mean in vivo toxicity studies are mandatory, though these guidelines are currently being updated. We reviewed our experiences working in the global regulatory environment, surveyed current practice, determined drivers for nonclinical in vivo studies with biosimilar mAbs and shared data on study design for 25 biosimilar mAbs currently in development. An in vivo toxicity study was carried out for all products, and a variety of study designs were used. The data demonstrates the practical challenges faced in obtaining regulatory approval for clinical trials based on in vitro data alone. The main reasons for carrying out in vivo studies were not based on scientific rationale, and we have therefore made recommendations for a more data-driven approach to the toxicological assessment of mAb biosimilars that minimises unnecessary use of animals and which can be used globally. Recently, we published the general approaches to quality risk management for the application of the single-use systems (SUS) in the manufacture of biologics. One of the quality-related issues resulting from the use of single-use components is the risk of residual impurities including leachables, insoluble particulate matter and insoluble visible matter. Particularly, a variety of chemicals or their derivatives used in the manufactures of single-use components such as polymeric catalysts, additives, anchoring agents and by-products from interactions with these chemicals may leach to the biologics products. Therefore, appropriate risk assessment for such impurities could be important for quality risk management of biologics. We gathered publicly available information about 168 chemicals of extractables/leachables from the SUS. As a comprehensive toxicity evaluation, these chemicals were evaluated by the three (Q)SAR softwares (Derek Nexus, CASE Ultra, ADME-WORKS) for genotoxicity. Only a few chemicals were predicted to be genotoxic, and most chemicals were judged as negative by two or all softwares. This initial screening results mean that most of leachables can be controlled by the qualification threshold (corresponding to a general toxicity threshold), which is proposed by the Product Quality Research Institute as toxicological risk assessment approach of parenteral drug products based on the threshold of toxicological concern (TTC) concept. However, about ten chemicals were predicted to have skin sensitization potential by the OECD QSAR toolbox. Although every chemical having skin sensitization potential may not always indicate sensitization potential by intravenous injection, more prudent risk assessment approach of sensitization potential for extractables/leachables should be developed. 
